Jardiance vs Metformin for Women: A Head-to-Head Comparison Across Every Life Stage

What Are These Two Drugs, and How Do They Work Differently?

Metformin and Jardiance lower blood sugar by completely different mechanisms, and those differences matter for how each drug behaves in a woman's body across different hormonal states.

Metformin (biguanide class) primarily suppresses glucose output from your liver, a process called hepatic gluconeogenesis. It also modestly improves insulin sensitivity in muscle tissue and slows intestinal glucose absorption. It does not stimulate insulin secretion, so the risk of hypoglycemia when used alone is very low.

Jardiance (empagliflozin, SGLT2 inhibitor class) blocks a protein in your kidney called SGLT2, which normally reabsorbs glucose back into your bloodstream. By blocking it, Jardiance causes your kidneys to excrete roughly 70-90 grams of glucose per day in urine [1]. This glucose loss also produces a mild osmotic diuresis and a drop in blood pressure.

Why the Mechanism Matters for Women Specifically

The urinary glucose excretion from Jardiance creates a warm, sugar-rich environment in the vaginal area. Women taking Jardiance have a significantly higher rate of vulvovaginal candidiasis (yeast infections) compared to placebo, roughly a 5-10 fold increase in clinical trials [2]. If you are already prone to recurrent yeast infections, this is a real and practical concern your clinician should address before you start.

Metformin does not carry this risk. Its side effects are mostly gastrointestinal: nausea, diarrhea, and abdominal cramping, which affect up to 25% of users but usually improve within 4-6 weeks and are minimized by taking the extended-release formulation with food [3].

Blood Sugar and A1C: Which Drug Works Harder?

Metformin typically lowers A1C by 1.0 to 2.0 percentage points from baseline, making it the most potent single oral agent for glucose lowering in most clinical studies [4]. Jardiance produces a more modest reduction of approximately 0.5 to 1.0 percentage points [5].

So if your primary goal is glucose control alone, metformin wins on efficacy per dollar.

Where Jardiance Pulls Ahead

Jardiance's cardiovascular and kidney benefits are not about glucose control at all. The EMPA-REG OUTCOME trial enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease. Empagliflozin reduced the risk of cardiovascular death by 38% and reduced hospitalization for heart failure by 35% compared with placebo, on top of standard care [6]. These results emerged within the first few months of treatment, far faster than any glucose-lowering effect could explain.

Metformin's landmark cardiovascular data come from the UKPDS 34 trial, which followed overweight adults with newly diagnosed type 2 diabetes. Metformin reduced myocardial infarction risk by 39% versus conventional diet therapy over a median of 10.7 years [7]. However, most UKPDS participants were men, and the trial design does not translate directly to women with established cardiovascular disease.

A Note on Sex-Specific Data Gaps

Women made up only about 24% of the EMPA-REG OUTCOME population. The cardiovascular benefit appeared consistent across sexes in subgroup analyses, but the trial was not powered to detect sex-specific differences. Women have been historically underrepresented in cardiovascular outcome trials for diabetes medications, and WomanRx flags this gap honestly: what we apply to women is largely extrapolated from male-predominant data.

Weight: Real Differences, Real Relevance for Women

Weight management is not a vanity issue. For women with type 2 diabetes, PCOS, or metabolic syndrome, excess adiposity drives insulin resistance, worsens hormonal imbalances, and accelerates cardiovascular risk after menopause.

Metformin produces modest, variable weight loss. In the Diabetes Prevention Program (DPP), metformin users lost an average of 2.1 kg over 2.8 years, compared to 5.6 kg in the lifestyle-intervention group [8]. For some women, weight remains stable or increases, particularly if metformin's GI side effects lead to dietary compensation.

Jardiance produces more consistent weight loss, averaging 2-3 kg in clinical trials, almost entirely from fat mass and fluid, not muscle [9]. The caloric loss from urinary glucose excretion (roughly 280-360 kcal/day) drives this effect, and it is largely sustained as long as the drug is continued.

Jardiance vs Metformin by Life Stage

Reproductive Years (Ages 18-40): PCOS and Fertility

Metformin is the drug with the evidence base for women with polycystic ovary syndrome (PCOS). It reduces insulin resistance, lowers circulating androgens, and can restore regular ovulation. A Cochrane review of metformin for PCOS found it significantly improved ovulation rates compared to placebo, and the combination of metformin plus clomiphene improved live birth rates over clomiphene alone in insulin-resistant women [10].

Jardiance has no comparable data in PCOS. A handful of small pilot studies exist, but no randomized controlled trials have assessed empagliflozin for ovulation, androgen levels, or fertility outcomes in women with PCOS. Prescribing Jardiance for PCOS off-label at this time is not supported by evidence.

If you are in your reproductive years with PCOS, metformin is the more appropriate choice between these two drugs.

Trying to Conceive

Metformin is often continued through early pregnancy in women with PCOS, though evidence on first-trimester outcomes is mixed. Jardiance should be discontinued before attempting conception. See the full pregnancy section below.

Perimenopause (Typically Ages 45-55)

Perimenopause brings fluctuating estrogen and progesterone levels, increasing visceral fat accumulation, worsening insulin resistance, and a sharply rising cardiovascular risk profile. The Menopause Society notes that women's 10-year cardiovascular risk rises steeply in the decade after the final menstrual period [11].

For a perimenopausal woman who has type 2 diabetes or prediabetes and already has cardiovascular risk factors, the kidney and heart-protective effects of Jardiance become more clinically relevant. The modest visceral fat reduction with Jardiance may also help offset the centralization of fat that estrogen decline drives.

Metformin remains the appropriate first-line choice. However, if a perimenopausal woman has established coronary artery disease, heart failure, or chronic kidney disease, adding Jardiance (or switching to it as the lead agent) is supported by current ADA Standards of Care 2024 [12].

Post-Menopause

After menopause, cardiovascular disease is the leading cause of death in women with type 2 diabetes. Both drugs are used in post-menopausal women, but the indication for Jardiance is stronger in those with existing heart or kidney disease.

Bone density is a separate concern. SGLT2 inhibitors including empagliflozin have been associated with increased fracture risk in some analyses, possibly through effects on calcium and phosphate handling. A post-menopausal woman already at elevated fracture risk (low bone density, history of fragility fracture) warrants a discussion with her clinician before starting Jardiance [13].

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is mandatory reading if you are pregnant, breastfeeding, or could become pregnant.

Jardiance in Pregnancy

Jardiance is contraindicated during the second and third trimesters of pregnancy. Animal studies demonstrated fetal harm, and there are no adequate human data from controlled trials in pregnant women [14]. The FDA label carries a specific warning against use in the second and third trimesters. First-trimester data in humans are very limited. If you become pregnant while taking Jardiance, stop it immediately and contact your clinician.

If you are of reproductive age and sexually active, reliable contraception is required while taking Jardiance unless you have confirmed infertility.

Metformin in Pregnancy

Metformin is used off-label in pregnancy for gestational diabetes mellitus (GDM) and for PCOS. It crosses the placenta, reaching fetal concentrations that approximate maternal levels. The MiG trial (Metformin in Gestational Diabetes) showed non-inferiority to insulin for GDM management, with less maternal weight gain and fewer hypoglycemic episodes [15].

However, long-term follow-up data from offspring exposed to metformin in utero show small but measurable differences in adiposity by age 9. This is an active area of research and a genuine evidence gap. Many OB-GYNs and maternal-fetal medicine specialists still prefer insulin as the primary pharmacologic agent in GDM, using metformin when insulin is declined or unavailable.

Lactation

Metformin is present in breast milk in small amounts, with infant exposure estimated at roughly 0.3-0.7% of the maternal weight-adjusted dose. Available data have not shown adverse effects in breastfed infants, and both the WHO Essential Medicines list and ACOG consider metformin compatible with breastfeeding [16].

Jardiance transfer into human breast milk is unknown. Given the pharmacologic class and the absence of data, Jardiance is not recommended during breastfeeding. Discontinuation is advised, or breastfeeding should be considered in the context of this unknown risk.

Contraception Note

Women taking either drug for type 2 diabetes who are of reproductive age should have an explicit conversation with their clinician about contraception. This is especially true for Jardiance given the pregnancy contraindication and the known PCOS-related fertility variability with metformin use.

Kidney Function: A Critical Variable for Women

Women develop diabetic kidney disease at rates similar to men but are more likely to be under-diagnosed because standard creatinine-based eGFR formulas may overestimate kidney function in smaller-bodied women. Both drugs have eGFR thresholds that determine safe use.

Metformin is contraindicated if eGFR is below 30 mL/min/1.73m² (risk of lactic acidosis) and should be used with caution between eGFR 30-45 [17]. Jardiance loses its glucose-lowering efficacy at eGFR below 45, though it retains kidney-protective effects at lower eGFR in people with established diabetic kidney disease [18].

For a woman with an eGFR between 30 and 45, Jardiance may still be appropriate for kidney protection even though it will not lower her A1C much. Metformin at that same eGFR level requires clinician judgment and dose reduction.

Cardiovascular Disease: When Jardiance Becomes the Priority

The following decision framework is not available in any current competitor article and was developed by the WomanRx clinical board for practical use in our patient population:

WomanRx Life-Stage CV Risk Framework for Choosing Between These Two Drugs

| Life Stage | CV Risk Profile | Preferred Starting Agent | |---|---|---| | Reproductive years, no CV disease, PCOS | Low-moderate | Metformin | | Reproductive years, no CV disease, no PCOS | Low-moderate | Metformin | | Perimenopause, no established CV disease | Moderate | Metformin; reassess if CV risk rises | | Perimenopause or post-menopause, established CVD or HF | High | Jardiance (add or switch per ADA) | | Any age, eGFR 30-60 + diabetic kidney disease | High | Jardiance for kidney protection; metformin per eGFR threshold | | Any age, pregnant or planning pregnancy | N/A | Metformin (with clinician supervision) or insulin; stop Jardiance |

This framework is a guide for conversation with your clinician, not a substitute for individualized assessment.

Switching from Jardiance to Metformin: When and How

Some women switch from Jardiance to metformin because of cost, recurrent yeast infections, urinary tract infections, or a pregnancy plan. Others switch the opposite direction after a cardiovascular diagnosis.

Reasons to Switch from Jardiance to Metformin

• Cost: Jardiance costs roughly $550 per month without insurance. Generic metformin costs $4-$10 for the same period.
• Recurrent vulvovaginal candidiasis: If yeast infections become frequent and new, the osmotic vaginal environment from SGLT2 inhibition may not be tolerable long-term.
• Pregnancy planning: Jardiance must be stopped. Metformin may be continued with OB supervision depending on your situation.
• eGFR declining below 45: Jardiance stops being effective for glucose lowering.
• Fournier's gangrene or recurrent UTI: Rare but serious genitourinary complications from SGLT2 inhibitors warrant discontinuation.

How the Switch Works Clinically

Your clinician will typically start metformin at 500 mg once daily with the evening meal and titrate by 500 mg per week to a target of 1,500-2,000 mg/day in divided doses, or use the extended-release formulation to improve tolerability. Jardiance is stopped when metformin is initiated, though some clinicians overlap for a few days to maintain glucose continuity. Expect A1C to rise slightly during the transition if Jardiance was providing meaningful glucose lowering.

Reasons to Switch from Metformin to Jardiance

• New cardiovascular event (MI, heart failure hospitalization): ADA 2024 guidelines recommend adding an SGLT2 inhibitor regardless of A1C [19].
• Progression to chronic kidney disease (eGFR 30-60 with albuminuria): Jardiance reduces the rate of kidney function decline.
• Metformin intolerance: Persistent GI side effects even on extended-release formulation.
• Inadequate A1C control on metformin alone: Jardiance is commonly added rather than substituted.

Side Effect Profiles for Women: A Practical Side-by-Side

| Side Effect | Metformin | Jardiance | |---|---|---| | Nausea/diarrhea | Common (up to 25%), usually improves | Uncommon | | Yeast infections (vaginal) | Not associated | Significantly elevated risk (5-10x vs placebo) | | Urinary tract infections | Not associated | Modestly elevated risk | | Hypoglycemia (alone) | Very low risk | Very low risk | | Weight change | Modest loss or neutral | Consistent 2-3 kg loss | | Vitamin B12 deficiency | Long-term risk (up to 30% reduction in levels after 4 years) | Not associated | | Fracture risk | No signal | Possible signal in post-menopausal women | | Blood pressure | Minimal effect | Modest reduction (systolic 3-5 mmHg) | | Diabetic ketoacidosis | Not associated | Rare but possible (euglycemic DKA) |

Women taking metformin long-term should have B12 levels checked every 1-2 years, as deficiency can mimic peripheral neuropathy and is often missed [20].

Who Is Each Drug Right For?

Metformin Is a Strong Match If You:

• Have newly diagnosed type 2 diabetes or prediabetes with no established cardiovascular or kidney disease
• Have PCOS and are trying to restore ovulation or improve androgen levels
• Are pregnant or planning to become pregnant
• Are on a tight budget
• Are in your reproductive years and want an option compatible with breastfeeding
• Have already had cardiovascular disease but cannot afford Jardiance

Jardiance Is a Strong Match If You:

• Have established cardiovascular disease (prior MI, angina, stroke, or peripheral artery disease)
• Have heart failure (reduced or preserved ejection fraction)
• Have chronic kidney disease with albuminuria and eGFR above 20
• Are post-menopausal with high cardiovascular risk and your A1C is not well-controlled on metformin alone
• Can tolerate and manage the higher yeast infection risk

Neither Drug Is Ideal If You:

• Are in the second or third trimester of pregnancy (use insulin or discuss with maternal-fetal medicine)
• Have an eGFR below 30 (both are generally avoided; Jardiance is contraindicated, metformin is contraindicated)
• Have type 1 diabetes (neither is approved as primary therapy; metformin is sometimes added off-label)

What Clinicians Are Saying

"The choice between empagliflozin and metformin is not a competition. For most women starting treatment for type 2 diabetes, metformin is still the first drug. But the moment a patient has a cardiovascular or kidney diagnosis, the conversation changes entirely."

The 2024 ADA Standards of Care state directly: "For patients with type 2 diabetes and established cardiovascular disease... An SGLT2 inhibitor... With demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen" regardless of A1C or background therapy [21].

Dr. Elena Vasquez, WomanRx clinical reviewer and reproductive endocrinologist, notes: "Women with PCOS often come to me already on metformin and ask whether Jardiance is better. My answer is almost always no, not yet. Metformin has decades of safety data in this population, it supports ovulation, and it is safe to continue if conception occurs. Jardiance has none of that foundation in PCOS, and it has to be stopped before pregnancy. That is a significant practical limitation for younger women who want future pregnancies."

Cost and Access Considerations

Cost is not a footnote. It is a clinical barrier. A woman who cannot afford her medication every month will have worse A1C than one on a cheap but effective drug she actually takes.

Generic metformin immediate-release 1,000 mg twice daily: approximately $4-$10 per month at most US pharmacies with a GoodRx coupon. Metformin extended-release is slightly more, typically $10-$25 per month.

Jardiance 10 mg or 25 mg: approximately $550-$600 per month without insurance. With commercial insurance, copays vary widely. Eli Lilly (Jardiance's manufacturer) offers a savings card that can reduce cost to $35/month for commercially insured patients, but this does not apply to Medicare or Medicaid beneficiaries, who make up a substantial portion of older women with type 2 diabetes.

For women on Medicare Part D who have established cardiovascular or kidney disease, Jardiance may be covered with a manageable copay under a formulary tier, but this requires checking your specific plan.